Clinical Trial Update: A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, and efficacy of orally administered OPC-67683 for tuberculosis, including multidrug-resistant cases, has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multidrug-resistant Tuberculosis
• Tuberculosis

Drugs mentioned

• OPC-67683 (delamanid)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Tuberculosis, Multidrug-Resistant | Phase 2 | Status: COMPLETED | Results posted: 2021-11-01